Jon Weeks
Long Snapper
Age: 34
Free Agency: 2021 (UFA)
Accrued Seasons: 9
- Height: 5-10
- Weight: 246
- College: Baylor
- Entry: 2010 Undrafted Free Agent (Texans)
- 2020 Salary Cap Charge: $750,000 (0.34% of cap)
- 2020 Cash Payout: $1,050,000 (0.44% of spending)
- 2020 Cash to Cap Ratio: 1.40
- Contract Value: $1,050,000 ($1,050,000 APY)
- Fully Guaranteed Money: $112,500
- Contract Ranking: 17/39 at LS
Current Contract
(SFA, signed 2020)
(📝: indicates contract trigger occuring during that year)| Year | Age | Base Salary | Guaranteed Salary | Cap Number | Cap % | Dead Money & Cap Savings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | 34 | $1,050,000 | $112,500 | $750,000 | 0.3% | |||||
| Total | $1,050,000 | $112,500 | $750,000 | |||||||
Contract Notes
Jon Weeks signed a one year contract with the Houston Texans on March 18, 2020 worth $1,187,500 with $250,000 guaranteed. Contract qualifies for the veteran salary benefit.Career Earnings: $7,987,500
Career APY: $887,500
Potential Earnings: $7,850,000
Total Guarantees: $692,500
Largest Cash Payment: $1,075,000 (2015)
Largest Cap Number: $980,000 (2019)
Contract History
| Team | Contract Type | Status | Year Signed | Yrs | Total | APY | Guarantees | Amount Earned | % Earned | Effective APY |
|---|---|---|---|---|---|---|---|---|---|---|
| Texans | Extension | Expired | 2015 | 4 | $3,900,000 | $975,000 | $330,000 | $4,645,000 | 119.1% | $929,000 |
| Texans | UFA | Terminated | 2020 | 1 | $1,187,500 | $1,187,500 | $250,000 | $0 | 0.0% | $0 |
| Texans | SFA | Active | 2020 | 1 | $1,050,000 | $1,050,000 | $112,500 | $1,050,000 | 100.0% | $1,050,000 |
Earnings By Team
| Team | Yrs | Salary | APY | Paid on Cap | % Paid on Cap | Paid as Dead Money | % Paid as Dead Money |
|---|---|---|---|---|---|---|---|
| Texans | 9 | $7,987,500 | $887,500 | $7,550,000 | 0.0% | $137,500 | 0.0% |
Salary Cap History
| Year | Team | Base Salary | Prorated Bonus | Guaranteed Salary | Cap Number | Cap % | Cash Paid | ||
|---|---|---|---|---|---|---|---|---|---|
| 2012 | Texans | $540,000 | $63,750 | $0 | $603,750 | 0.5% | $795,000 | ||
| 2013 | Texans | $630,000 | $63,750 | $0 | $693,750 | 0.6% | $630,000 | ||
| 2014 | Texans | $730,000 | $63,750 | $0 | $793,750 | 0.6% | $730,000 | ||
| 2015 | Texans | $825,000 | $113,750 | $80,000 | $938,750 | 0.6% | $1,075,000 | ||
| 2016 | Texans | $825,000 | $50,000 | $0 | $875,000 | 0.6% | $825,000 | ||
| 2017 | Texans | $900,000 | $50,000 | $0 | $950,000 | 0.5% | $900,000 | ||
| 2018 | Texans | $915,000 | $50,000 | $0 | $965,000 | 0.5% | $915,000 | ||
| 2019 | Texans | $930,000 | $50,000 | $0 | $980,000 | 0.5% | $930,000 | ||
| 2020 | Texans | $1,050,000 | $0 | $112,500 | $750,000 | 0.3% | $1,050,000 | ||
| Total | $7,345,000 | $505,000 | $192,500 | $7,550,000 | $7,850,000 | ||||
Dead Money History
| Team | Year | Cap Charge | Cash Paid |
|---|---|---|---|
| Texans | 2020 | $137,500 | $137,500 | Total | $137,500 | $137,500 |
Statistics
| Year | Games Played | Games Missed | Snaps | |
|---|---|---|---|---|
| Injured | Healthy | Special | ||
| 2012 | 16 | -- | -- | 34.8% |
| 2013 | 16 | 0 | 0 | 31.4% |
| 2014 | 16 | 0 | 0 | 35.2% |
| 2015 | 16 | 0 | 0 | 33.9% |
| 2016 | 16 | 0 | 0 | 31.4% |
| 2017 | 16 | 0 | 0 | 31.6% |
| 2018 | 16 | 0 | 0 | 32.1% |
| 2019 | 16 | 0 | 0 | 30.7% |
| 2020 | 16 | 0 | 0 | 29.2% |
Valuation Diamond
The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.
| OTC Valuation | APY | |
|---|---|---|
| Regular | $959,000 | $1,050,000 |
| Injury Adjusted | $959,000 | $1,050,000 |
test
Weekly Valuation Trends
The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.
To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.